Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“Another new anti-HER2 therapy…
SHR-A1811 (Phase 1, HORIZON-X):
- mPFS: 25 months (HER2+), 11 months (HER2-low)
But the real question now is how will we choose among all these anti-HER2 options?
- Which patient, which biomarker?
- HER2 IHC, mutation, or liquid biopsy?
- Brain metastases, visceral disease?
- What is the optimal sequencing?
The problem is no longer new drugs… it’s how we choose.
This may well be one of the greatest challenges in the future of oncology.”
Title: SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial
Authors: Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Yongmei Yin, Min-Hee Ryu, John J. Park, Shusuan Jiang, Jee Hyun Kim, Shouman Wang, Yahua Zhong, Mark Voskoboynik, Jian Zhang, Andreas Kaubisch, Caigang Liu, Yu Chen, Seock-Ah Im, Lingying Wu, Yingbin Liu, Vinod Ganju, Minal Barve, Hui Li, Guangyu Yao, Mudan Yang, Lequn Bao, Yiming Zhao, Jianli Zhao, Kaijing Zhao, Yu Shen, Shangyi Rong, Xiaoyu Zhu and Erwei Song.
Other articles featuring Ahmet Dirican on OncoDaily.
